4435-59-0

Basic information

• Product Name: Benzenesulfonyl chloride, 4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-
• CAS NO: 4435-59-0
• Molecular Formula: C14H8ClNO4S
• Molecular Weight: 321.741
• Mol File: 4435-59-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzenesulfonyl chloride, 4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonyl chloride, 4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-(4435-59-0)
• EPA Substance Registry System: Benzenesulfonyl chloride, 4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-(4435-59-0)

Safety Data

• Hazardous Substances Data: 4435-59-0(Hazardous Substances Data)

Upstream product

• 62-53-3 aniline 
• 85-44-9 phthalic anhydride 
• 86581-47-7 4-(1,3-dioxoisoindolin-2-yl)benzenesulfonic acid 
• 520-03-6 N-phenylphthalimide 

Downstream Products

• 396135-20-9 N-(N,N-phthaloyl-sulfanilyl)-sulfanilic acid amide 
• 111721-80-3 4-(1,3-dioxoisoindolin-2-yl)-N-phenylbenzenesulphonamide 
• 4479-70-3 4-(1,3-dioxobenzo[c]azolidin-2-yl)benzenesulfonamide 
• 1394345-33-5 C₂₄H₁₈N₄O₉S₂ 
• 206361-99-1 darunavir 
• 1430810-44-8 2-(4-((2-methylpiperidin-1-yl)sulfonyl)phenyl)isoindoline-1,3-dione 

Relevant articles and documents

Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues.

This paper describes the synthesis and anti-inflammatory activity of new N-phenyl-phthalimide sulfonamides (3a-e) and the isosters N-phenyl-phthalimide amides (4a-e), designed as hybrids of thalidomide (1) and aryl sulfonamide phosphodiesterase inhibitor (2). In these series, compound 3e (LASSBio 468), having a sulfonyl-thiomorpholine moiety, showed potent inhibitory activity on LPS-induced neutrophil recruitment with ED(50)=2.5mg kg(-1), which was correlated with its inhibitory effect on TNF-alpha level.

A NOVEL PROCESS FOR THE PREPARATION OF HIV PROTEASE INHIBITOR AND INTERMEDIATES THEREOF

The present invention relates to process for the preparation of Darunavir or a solvate thereof of Formula (I) using a novel intermediate (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (2S,3R)-4-(4-(1,3-dioxoisoindolin-2-yl)-N-isobutylphenylsulfonamido)-3 -hydroxy- 1 -phenylbutan-2- ylcarbamate Compound of formula (II): The present invention also relates to the process for the preparation of novel intermediates (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (2S,3R)-4-(4-(l,3-dioxo iso indolin-2-yl)-N-isobutylphenylsulfonamido)-3 -hydroxy-1-phenylbutan-2-ylcarbamate Compound of formula (II). Darunavir or its solvate of formula (I) are useful therapeutic agent and used in treatment of antiviral diseases.

Synthesis and molecular modelling studies of novel sulphonamide derivatives as dengue virus 2 protease inhibitors

Abstract Development of antivirals for dengue is now based on rational approach targeting the enzymes involved in its life cycle. Among the targets available for inhibition of dengue virus, non-structural protein NS2B-NS3 protease is considered as a promising target for the development of anti-dengue agents. In the current study we have synthesized a series of 4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)benzene-1-sulphonamide derivatives and screened for DENV2 protease activity. Compounds 16 and 19 showed IC50 of DENV2 Protease activity with 48.2 and 121.9 μM respectively. Molecular docking and molecular dynamic simulation studies were carried out to know the binding mode responsible for the activity. MD simulations revealed that, NS2B/NS3 protease was more stable when it binds with the active compound. Structure optimization of the lead compounds 16 and 19 and their co-crystallization studies are underway.